This Article  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

John Henahan

JAMA. 1981;246(20):2311-2315.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

A reduction in the expected number of "coronary events" among patients at high risk for heart disease is ascribed to the drug probucol, according to a Finnish study presented at a recent international conference on lipoproteins and coronary atherosclerosis in Lugano, Switzerland. Since the agent also lowered the patients' high-density lipoprotein (HDL)-cholesterol levels, the findings question the growing belief that high levels of HDL may protect against heart disease.

In the five-year study, the incidence of sudden death and fatal and nonfatal myocardial infarction among 184 persons who took probucol in conjunction with a low-cholesterol diet was calculated as 9 per 1,000 per five years, said Dr Tatu Miettinen of the Second Department of Medicine, University of Helsinki. According to a risk index calculated on the basis of initial cholesterol levels, age, weight, blood pressure, and other factors, the expected coronary incidence in this group would have been 18±15 per . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?